Pharma Strategy Blog

Commentary on Pharma & Biotech Oncology / Hematology New Product Development

  • Featured
  • Blog
  • About
  • KOL Interviews
  • Video
  • ASCO 2013
  • Icarus Consultants
  • Contact
  • Sign Up
  • Understanding how PD-1 and PD-L1 immunotherapy works.

    ASCO 2013 Highlights PD-1 and PD-L1 immunotherapy

    Read more
  • AACR Washington DC Cherry Blossoms

    Reflections of a Medical Oncologist on AACR 2013

    Read more
  • Lung cancer, Source Wikipedia

    Overcoming drug resistance in lung cancer

    Read more
  • Washington DC Cherry Blossoms 2013

    Overcoming resistance to vemurafenib in metastatic melanoma

    Read more
  • DC In Springtime

    AACR 2013 – some initial thoughts on the emerging trends

    Read more
  • ZIOP

    Palifosfamide – a predictable miss in soft tissue sarcoma?

    Read more
  • CallonCongress HR1070

    Help make colonoscopies more affordable as an effective screening tool

    Read more
  • Source: Cell

    Bromodomain Inhibitors – an exciting new target in cancer research?

    Read more
  • ARRY-520 Phase II study design presented at ASH 2012

    ASH 2012 update on ARRY-520 in multiple myeloma

    Read more
  • Results from tivozanib TIVo-1 trials with biomarker analysis

    Will biomarkers revolutionalise treatment with tivozanib?

    Read more
  • Tivozanib v sorafenib phase 3 renal cancer data

    ASCO GU update on tivozanib in advanced clear cell renal cancer

    Read more
  • Tumor Lysis Syndrome in CLL CTL019

    Tumor Lysis Syndrome – what is it and why is it important in cancer research?

    Read more
  • Professor Bertrand Tombal

    Making a difference in Advanced Prostate Cancer – an interview with Bertrand Tombal

    Read more
  • ASCO GI 2013 Symposium

    Will ASCO GI herald a new era for pancreatic cancer?

    Read more
  • Source: Jänne et al., (2012)

    Effectively targeting KRAS in lung cancer with a MEK inhibitor

    Read more
  • Should we develop Minimally Effective Dose in cancer research

    Time to rethink cancer clinical trials strategy?

    Read more
  • NCCN Guidelines for Colon Cancer

    Zaltrap – a simple dosing error or not?

    Read more
  • ESMO 2012 Pancreatic Cancer Satellite Symposium

    Prospect of Abraxane in Pancreatic Cancer excites ESMO 2012

    Read more
  • AACR 2012 Threshold TH-302 Pancreatic

    Highlights of AACR 2012 – Part 3

    Read more
  • Biology of Pancreatic Cancer

    The biology of pancreatic cancer

    Read more
E
Understanding how PD-1 and PD-L1 immunotherapy works.

ASCO 2013 Highlights PD-1 and PD-L1 immunotherapy

Update on progress with PD-1 and PD-L1 immunotherapies at ASCO 2013.

View post
E
AACR Washington DC Cherry Blossoms

Reflections of a Medical Oncologist on AACR 2013

Guest post on AACR 2013 by Philippe Aftimos, MD a medical oncologist at Institut Jules Bordet in Brussels with his reflections on new developments in cancer biomarkers and clinical trial design.

View post
E
Lung cancer, Source Wikipedia

Overcoming drug resistance in lung cancer

Update on new techniques for identifying and overcoming resistance in advanced lung cancer

View post

Terms of Use
Copyright © 2006-13 Pharma Strategy Blog